Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATH434 in Early-Stage Multiple System Atrophy
NCT05109091Phase 2Completed
- Sponsor
- Alterity Therapeutics
- Start
- Jul 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of ATH-434 in multiple system atrophy (MSA), sponsored by Alterity Therapeutics. Started Jul 2022; status: completed.
02
Drugs
ATH-434
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT05109091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05109091.